EmPRO CEO Shulan Honored with “Trailblazer Award” at Chinese American Medical Society and Coalition of Asian-American IPA Annual Red Lantern Gala
November 14, 2023
byIn a grand celebration at Pier 60 Chelsea Piers in New York City, Bruce Shulan, president and chief executive officer of EmPRO
Insurance Company, was honored with the distinguished "Trailblazer Award" at the Chinese American Medical Society (CAMS) and Coalition of Asian-American IPA (CAIPA) annual Red Lantern Gala on November 4. The event highlighted the outstanding achievements of Shulan and also marked the significant milestone of CAMS' 60th Anniversary.
"This recognition by CAMS and CAIPA is deeply meaningful to me as their commitment to eliminating health disparities and advancing medical knowledge, especially within the Chinese American community, mirrors the values we uphold at EmPRO,” said Shulan upon receiving the award. “It's not individual achievements, but collective effort of a great team that makes a real difference."
Established in 1963, the CAMS mission is to improve the health status of Chinese Americans and to promote excellence in healthcare for all. The society's primary objectives include eliminating health disparities of Chinese Americans and other underserved populations, advancing medical knowledge through education, research, scholarship and philanthropy with a specific focus on aspects unique to Chinese Americans, and promoting and advocating for medical professionals of Chinese descent and like-minded individuals.
CAIPA is one of the most successful independent practice associations in Greater New York with over 1,800 private practice providers, covering over 70 specialties. CAIPA provides medical services and care to about half-a-million patients in the Asian community.
"CAMS and CAIPA’s shared mission and commitment is truly inspiring,” Shulan added. “Through education and philanthropy, these organizations have showcased the importance of unity in achieving a common goal, and I'm both humbled and invigorated to be associated with these great organizations."
Shulan's recognition as a trailblazer in the medical malpractice industry resonates with his impressive professional journey. A senior executive, Shulan has a remarkable history of steering insurance businesses through transformative periods, fostering stability and sparking substantial growth. Under his leadership at EmPRO, the company has demonstrated a commitment to financial discipline, operational enhancements, outstanding customer service and state-of-the-art technology.
team and company as a whole,” said Kirk Tweedy, Integris Group chief operating officer. “Christina’s passion for defending physicians makes her an ideal fit for our company, where we are confident she will continue her legacy of providing a robust defense to physicians and medical facilities.”
has worked as trial counsel for three prominent insurance in-house defense firms and has been responsible for all aspects of insurance defense litigation including coverage analysis, trials and appeals. In his most recent role, Kevin worked closely with the company's all-physician board of directors and found the mission of defending the interests of medical providers to be the most rewarding work of his career. His educational credentials include a Juris Doctor from the University of Florida Levin College of Law, further supported by bar admission in Connecticut.
mutual ownership, client service and innovation to create an even stronger combined company. The merged organization now serves more than 50,000 physicians, healthcare providers and organizations across the U.S.
medical errors. The endorsement signifies a shared commitment between MedPro Group and I-PASS to reduce communication-related adverse events that contribute to patient harms.
work preventing central line-associated bloodstream infections (CLABSI). Healthcare providers had been making strides in reducing infections associated with central lines; however, in the third quarter of 2020, the CDC reported a 53% increase in the number of CLABSI, compared to the same group of hospitals in 2019. Of all the hospital-associated infections, the CLABSI rate increased the most. The heightened CLABSI incidence is likely attributed to a lack of infection prevention activities involving central line insertion and maintenance practices.